Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A.M. Liberati

Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS and Minimal Residual Disease Negativity in Patients With Previously Untreated CLL and Comorbidities

Hematological Oncology

English

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)

Hematological Oncology

English

Related publications

Obinutuzumab Plus Bendamustine in Previously Untreated Patients With CLL: A Subgroup Analysis of the GREEN Study

English

Ongoing Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Hematological Oncology

English

Sakk 35/15: A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Hematological Oncology

English

Venetoclax–Obinutuzumab Elicits High Response Rates in CLL

Cancer Discovery

Oncology

2019

English

Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia

English

High Efficacy of Venetoclax Plus Obinutuzumab in Patients With Complex Karyotype (Ckt) and Chronic Lymphocytic Leukemia (Cll): A Prospective Analysis From the Cll14 Trial

Hematological Oncology

English

Profile of Obinutuzumab for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

OncoTargets and Therapy

Oncology

Pharmacology

2015

English

Bendamustine (B), Followed by Obinutuzumab (G) and Venetoclax (A) in Patients With Chronic Lymphocytic Leukemia (Cll): Cll2-Bag Trial of the German CLL Study Group (Gcllsg)

Hematological Oncology

English

Venetoclax: Another Oral Therapy Option for Patients With CLL

Pharmacy Today

2016

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A.M. Liberati

Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS and Minimal Residual Disease Negativity in Patients With Previously Untreated CLL and Comorbidities

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)

Related publications

Obinutuzumab Plus Bendamustine in Previously Untreated Patients With CLL: A Subgroup Analysis of the GREEN Study

Ongoing Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Sakk 35/15: A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Venetoclax–Obinutuzumab Elicits High Response Rates in CLL

Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia

High Efficacy of Venetoclax Plus Obinutuzumab in Patients With Complex Karyotype (Ckt) and Chronic Lymphocytic Leukemia (Cll): A Prospective Analysis From the Cll14 Trial

Profile of Obinutuzumab for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

Bendamustine (B), Followed by Obinutuzumab (G) and Venetoclax (A) in Patients With Chronic Lymphocytic Leukemia (Cll): Cll2-Bag Trial of the German CLL Study Group (Gcllsg)

Venetoclax: Another Oral Therapy Option for Patients With CLL